Lung & Respiratory Disease Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

This Phase 3 trial is testing tezepelumab, a new biologic medicine, in children aged 5 to under 12 who have severe asthma that is not well controlled. If the treatment works as hoped, it could reduce the number of severe asthma attacks and lower the need for steroid medicines in these children. The study is recruiting 231 participants worldwide, making it easier for eligible children to join and access this potential new treatment.

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

This Phase 3 study is focused on young children between 2 and under 6 years old who have uncontrolled asthma or severe wheezing. It is testing dupilumab, another biologic treatment, to see if it can safely improve symptoms and reduce asthma attacks in this age group. The trial takes place in multiple countries and involves a year of treatment with ongoing follow-up to monitor effects.

Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa

This Phase 4 trial is exploring a less invasive treatment for premature infants who develop respiratory distress syndrome, a serious lung condition. The study tests a new way to give surfactant, a medicine that helps the lungs work better, which could be safer and easier to use especially in low-resource settings. Conducted in several African countries, the trial follows infants during their hospital stay to check for improved survival and safety outcomes.

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

This Phase 3 trial evaluates benralizumab, a biologic drug, in children aged 6 to under 18 with a specific type of severe asthma called eosinophilic asthma. The goal is to reduce asthma attacks and improve overall asthma control in those who continue to have severe symptoms despite current treatments. This global study includes children using high-dose inhaled corticosteroids who have a history of asthma flare-ups.

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma

This Phase 3 trial is looking at whether tezepelumab can help adolescents and adults aged 12 to 80 with severe asthma reduce their dependence on daily asthma medications while still keeping their asthma well controlled. The study is ongoing across several countries and aims to make life easier for people managing severe asthma by potentially lowering their medication burden.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.